Clinical Trials
Transforming Research Into Better Lives for WM Patients
Active WM-Net Clinical Trials
Innovative studies designed and led by academic investigators to bring new treatments within reach.
WM-Net coordinates a portfolio of multi-center clinical trials investigating next-generation therapies for Waldenström’s macroglobulinemia.
Preview ongoing studies here and follow links for eligibility details and enrollment sites.
Loncastuximab tesirine in previously treated WM
First trial using an ADC (antibody-drug conjugate) for WM in the world
Sites: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Mayo Clinic, Fred Hutchinson Cancer Center
Accrual status: 20 of 21 patients
Highlight: Oral presentation at ASH 2025
Zanubrutinib, Bendamustine, and Rituximab (ZEBRA) in previously untreated WM
First trial using a triple combination for WM in the US
Sites: Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Colorado Blood Cancer Institute. Pending at UT Southwestern
Accrual status: 42 of 55 patients
Epcoritamab in previously treated WM
First trial using an anti-CD20 bispecific antibody for WM in the world
Sites: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, UNC Medical Center. Pending at UT Southwestern, City of Hope
Accrual status: 5 of 20 patients
Pirtobrutinib, Venetoclax, and Rituximab (PROVEN) in previously untreated WM
First trial using a non-chemo, fixed-duration, triple combination for WM in the world
Sites: Memorial Sloan Kettering Cancer Center. Pending at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center
Accrual status: 5 of 40 patients
Etentamig in previously treated WM
First trial using an anti-BCMA bispecific antibody for WM in the world
Sites: Mayo Clinic, Dana-Farber Cancer Institute, MD Anderson, Memorial Sloan Kettering Cancer Center, The Ohio State University Wexner Medical Center, University of Miami Health System
Accrual Status: protocol review